Validation of Growth Differentiation Factor (GDF-15) as a Radiation Response Gene and Radiosensitizing Target in Mammary Adenocarcinoma Model by Hargita Hegyesi et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
20 
Validation of Growth Differentiation 
Factor (GDF-15) as a Radiation Response 
Gene and Radiosensitizing Target 
in Mammary Adenocarcinoma Model 
Hargita Hegyesi1, James R. Lambert2, Nikolett Sándor1, 
Boglárka Schilling-Tóth1 and Géza Sáfrány1 
1Frédéric Joliot-Curie National Research Institute for Radiobiology and Radiohygiene, 
2Department of Pathology, University of Colorado, 
Anschutz Medical Campus, Aurora, CO, 
1Hungary 
2USA 
1. Introduction  
In this chapter we summarize the role of cytokines in the radiation response, focusing in 
particular on growth differentiation factor-15 (GDF-15), and give a brief overview of our 
ongoing experiments in a mouse mammary carcinoma model. 
The principal function, receptor, and signaling pathway of GDF-15 remain uncertain, 
although several of its biological activities have already been described; the exact role of 
GDF-15 in cancer progression also remains poorly understood. Increased GDF-15 expression 
is a common feature of many cancers. Several studies have observed upregulation of GDF-
15 mRNA and protein in tumor biopsy. Serum GDF-15 levels are often markedly elevated in 
cases of metastatic cancer, and appear to occur in parallel with the stages and extent of 
disease, particularly in cases of prostate and melanoma [Senapati et al., 2010, Boyle et al., 
2009]. Indeed, a number of studies have described an antitumorigenic function for GDF-15, 
by which it induces apoptosis and may negatively affect tumor growth [Cekanova et al., 
2009, Jutooru et al., 2009]. 
Prevention by eliminating tumor promoters, early diagnosis and new target treatment are 
keys to reduce the numbers of deaths caused by breast cancer. In our present study, we 
propose that GDF-15 increases radioresistance. We demonstrate that down regulated mouse 
GDF-15 by RNA interference improves the radiosensitivity of the tumor in an LM2 mouse 
breast cancer model. In this regard, GDF-15 overexpression in breast cancer cell has been 
shown to supply important cytoprotective roles and resistance to radiation treatments. The 
paradoxical role of GDF-15 in breast cancer could be related to its pleiotropic effect on 
different signal pathway. 
Recent research has focused on molecular targets for radiation sensitization of cancer cells. It 
is of particular interest that several potential target proteins involved in radiation 
sensitization, which have been identified in growth related cellular signaling pathways.  
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2. Radiation response genes in breast cancer cells  
Radiation causes DNA damage, which activates ATM (ataxia telangiectasia mutated/ATR 
(ATM and Rad3-related) protein that in turn promotes activation of receptors/ intracellular 
signaling pathways and stimulates cell cycle checkpoints, p53 (tumor protein 53) activity, 
and DNA repair pathways. Radiation generates ionizing events in water in the cytosol that 
are amplified, thought to be mediated by mitochondria, which generate large amounts of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) that inhibit protein 
tyrosine phosphatase (PTPase) activities. In addition, radiation activates acidic 
sphingomyelinase and increases the production of ceramide. Inhibition of PTPases leads to a 
general derepression (activation) of receptor and nonreceptor tyrosine kinases and the 
activation of downstream signal transduction pathways. Radiation-induced ceramide has 
been shown to promote membrane-associated receptor activation by facilitating the 
clustering of receptors within lipid rafts [Balaban et al., 1996, Goldkorn et al., 1997]. 
The inducible alteration in gene expression is a fundamental molecular event of mammalian 
cells in response to ionizing radiation, and the fate of cells will at least partially depend 
upon the inducible changes in expression of some genes involved in these complex 
regulatory pathways resulting in cell cycle delays, cell killing or apoptosis and DNA repair 
[Chaudhry et al., 2003, Cucinotta et al., 2002 Vallat et al., 2003]. The cDNA microarray 
technology, allowing a large-scale expression profiling analysis, can provide tremendous 
information for elucidating the complex cellular response to radiation. Until now, a great 
number of radiation-inducible target genes have already been identified. Some of the 
inducible genes were identified in cells exposed to high and even supra-lethal doses of 
ionizing radiation (IR) [Roy et al., 2001]; low doses or low dose rates [Ding et al., 2005, 
Amundson et al., 2003, Mercier et al., 2004]. These reports provide very valuable 
information for understanding the precise mechanisms of the diverse effects of IR. A 
simultaneously comparative analysis of gene responses to radiation from low, medium to 
high doses should be more informative for identifying the inducible genes with a dose-
dependent expression. 
It is well known that the p53 tumor suppressor plays a key role in mediating apoptosis and 
the cell cycle checkpoint by various intracellular and extracellular signals including IR. A 
number of proteins have been identified to be involved in the p53 pathway, including 
Proliferating cell nuclear antigen (PCNA), Cyclin-dependent kinase inhibitor 1A 
(CDKN1A/p21), Murine double minute 2 (MDM2), GDF-15, Tumor necrosis factor receptor 
superfamily member 10B (TNFRSF10B/TRAIL-R2), Tumor protein p53 inducible protein 3 
(TP53I3/PIG3) and Growth arrest and DNA damage (GADD45) [Polyak et al., 1997, 
Contente et al., 2002]. In a microarray investigation showed that, only five genes were 
significantly induced by the radiotherapy in breast cancer tissue. The genes are DNA 
damage-binding protein 2 (DDB2), CDKN1A, GDF-15, Glutathione peroxidase 1 (GPX1) and 
Polo-like kinase 3 (PLK3) [Helland et al., 2006]. Additional studies demonstrated that the 
levels of mRNA and protein expression of PCNA, c-fos, c-Jun N-terminal kinase 2 (JNK2) 
and Fos-related antigen 1 (Fra-1) were increased in the mammary epithelial cell line 
compared to the levels in non-tumorigenic control cells. The transforming factor Rho A was 
significantly increased only in the tumor cell line. Furthermore, the levels of mRNA and 
protein expression of Human epidermal growth factor receptor 2 (ErbB2) were significantly 
increased in the transformed cell line and in tumor cells derived from the transformed cells 
after injecting them into nude mice [Yun et al., 2010]. A decrease in RbA/p48 protein 
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expression and mRNA levels was observed in cells treated with double doses of alpha 
particle radiation in the presence of estrogen, regardless of tumorigenicity. Furthermore, 
radiation increased c-myc, c-jun and c-fos protein expression in the c-Ha-ras- relative to non-
irradiated control cell line [Calaf & Hei, 2004]. 
The role that cytokines play in radiation toxicity was first discovered and described by 
Rubin and colleagues [Rubin et al, 1986]. Shortly thereafter, transforming growth factor ǃ1 
(TGF-1) was identified in the circulation of breast cancer patients who developed 
pulmonary and hepatic complications from chemotherapy for bone marrow transplantation 
[Anscher et al, 1993]. Chen and colleagues found that subjects undergoing thoracic radiation 
who had elevated interleukine-1 (IL-1) or IL-6 before or during radiation all developed some 
degree of radiation changes (clinical or radiographic). Angiogenic factors have also been 
associated with late pulmonary toxicity. For example, Fibroblast growth factor 2 (FGF2) was 
markedly elevated in the circulation of most subjects with severe late radiation fibrovascular 
toxicity of the extremities [Chen et al, 2002].  
Presently, we do not yet have adequate markers for the vast majority of clinical needs, and 
their discovery remains a very high priority in radiation research. The need for these 
markers has intensified due to the growing number of cancer survivors at risk for 
developing toxicity from radiation, chemotherapy, surgery, and combinations of all three. 
2.1 GDF-15 expression in different normal and malignant cells 
GDF-15 is expressed at high levels in placenta, macrophages, and epithelial cells. Its 
expression is very low in tumor cell lines originating from breast, cervix, and lung [Li et al., 
2000], but elevated in some metastatic colon and gastric cancers [Buckhaults et al., 2001, Lee 
et al., 2003). GDF-15 expression is rapidly induced by a variety of cellular stresses in a p53-
dependent and –independent manner, and it mediates cell cycle arrest and apoptosis in 
response to DNA damage, toxins, anoxia, liver injury, and other cellular stresses [Hsiao et 
al., 2000, Albertoni et al., 2002, Wilson et al., 2003]. GDF-15 induction may occur via Heat-
shock protein 70-2 (Hsp70-2) depletion. In HeLa cells Hsp70-2 depletion resulted in 
increased p53 protein levels and activity as measured by a reporter gene assay [Rohde et al., 
2005]. GDF-15 is a secreted protein that can inhibit tumor cell growth both in an autocrine 
and paracrine fashion [Tan et al., 2000]. Whereas the antiproliferative effect of GDF-15 
depends on the intact TGF- signaling pathway, receptor and mothers against 32 
decapentaplegic homolog 4 (Smad4), endogenously expressed GDF-15 is highly cytotoxic 
also in Smad4-null breast cancer cells [Li et al., 2005, Tan et al., 2000). Thus, therapeutic 
strategies targeting GDF-15 are likely to affect also cancer cells with defective TGF- 
signaling and additionally to induce a so-called bystander effect in GDF-15-responsive 
tumors. 
GDF-15 has been reported to be regulated by many chemicals at the transcriptional level [Li 
et al., 2000, Baek et al., 2001, Baek et al., 2004, Baek et al., 2005] and some of which are 
dependent on de novo protein synthesis [Newman et al., 2003] Transcriptional regulation of 
GDF-15 is complex, and the promoter sequence has many different cis- and trans-acting 
promoter elements [Baek et al., 2001]. Induction of GDF-15 expression by doxorubicin, 
hypoxia and the hypoxia mimetic, cobalt chloride in LNCaP prostate tumor cells strictly was 
dependent on functional p53. LNCaP cells expressing dominant negative p53 failed to 
induce GDf-15 mRNA and protein under all of these experimental conditions. Similarly, p53 
function was also required for induction of GDF-15 expression in response to high cell 
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density [Kelly et al., 2009]. In addition, GDF-15 seems to be a potentially important 
downstream target of three tumor suppressor genes. GDF-15 expression is regulated by the 
tumor suppressor genes p53 and early growth response (EGR) gene-1 [Baek et al., 2004]. 
Recently, was identified GDF-15 as a novel negative downstream target of the 
phosphatidylinositol 3-kinase/protein kinase B (AKT)/glycogen synthase kinase (GSK)-3ǃ 
pathway [Yamaguchi et al., 2004].  
The role of GDF-15 has been implicated directly with cancer, in which both antiapoptotic 
and proapoptotic effects have been described in a variety of tumor cell types. GDF-15 
induction by vitamin D via p53-dependent mechanism and inhibition of prostate cancer cell 
growth was reported previously [Lambert et al., 2006]. Experimental studies using human 
prostate LNCaP cells supported the role of GDF-15 in regulation of cell proliferation. 
Overexpression of GDF-15 by transfection in LNCaP-C33 cells induced aggressive cell 
growth, whereas knocking down GDF-15 in LNCaP-derived subclones (C81 and LNCaP-
Ln3: LNCaP cells highly metastasis to lymph nodes) using antisense oligonucleotides 
inhibited cell growth and proliferation [Chen et al., 2007]. Also, GDF-15 overexpression in 
colon cancer cell lines reduced the growth of xenograft tumors [Baek et al., 2001), but serum 
GDF-15 levels were positively correlated with tumor stage and metastasis [Brown et al., 
2003]. Despite ambiguous observations in various tumor cell types, data obtained from 
clinical studies has established that serum GDF-15 was the best diagnostic marker of bone 
metastasis in prostate cancer [Selander et al., 2007]. However in the tissue 
microenvironment various components individually and/or collectively cause tissue 
damage or injury, leading to inflammation. Inflammatory products, including GDF-15, 
could contribute to the tumor promotion environment. The tumorigenic function of GDF-15 
could be modified by educating the macrophages. Or another possibility is that, thus GDF-
15 is secreted from tumor cells together with vascular endothelial growth factor (VEGF) to 
promote vascular development mediated by serine/threonine-protein kinase B-Raf 
signaling as reported in malignant melanoma [Huh et al., 2010,]. 
Individual cancers have different levels of secreted GDF-15 protein because of differences in 
expression level and variation in the processing of mature GDF-15 [Bauskin et al., 2005]. 
Serum analyses of cancer patients showed a significant correlation between increased GDF-
15 protein levels and the metastatic progression of colorectal, breast, and prostate cancers 
[Welsh et al., 2003, Koopmann et al., 2004, Baek et al., 2009]. The association of cancer 
progression with GDF-15 expression resembles that of TGF-ǃ, which plays a role as a tumor 
suppressor during early stages of cancer and as a growth enhancer in later stages [Dumont 
& Artega 2003]. 
GDF-15 also induced the transactivation of HER2/neu (ErbB2 tyrosine kinase) in human 
breast and gastric cancer cells, and this activation stimulated Hypoxia-inducible factor 1- 
(HIF-1ǂ) protein accumulation and the expression of its target gene via the 
PI3K/Akt/mTOR and ERK-1/2 signaling pathways. These novel observations provide 
additional support for the notion that GDF-15 may operate as a positive regulator of tumor 
progression in certain ErbB2-overexpressing tumors, including breast and gastric cancers 
[Kim et al., 2008, Klos et al., 2006]. 
The increase of GDF-15 expression induced via environmental stimuli (irradiation, hypoxia, 
free radicals etc.) is indicated. Furthermore, several transcriptional factors have been shown 
to increase GDF-15 expression level in p53 –dependent or independent manner in cancer 
cells in vitro and in mice in vivo. Potentially GDF-15 is a downstream mediator of the 
radioprotection of LM2 tumor cells to DNA damage and oxidative stress. This suggests 
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GDF-15 has significant paracrine effects, which modulate the tumor environment; however 
what is clear, is that there is a strong evidence for GDF-15 measurement in blood and tissues 
to detect and monitor cancer progression. 
 
 
Fig. 1. Pleiotropic effect of GDF-15 overexpression.  
3. Research result 
3.1 Characteristics of LM2 cells as a model of breast cancer 
Several years ago a mammary tumor cell line, LM2, derived from M2 mammary 
adenocarcinoma which spontaneously appeared in a Balb/c female mouse was described 
[Galli et al., 2000]. The LM2 cell line has been maintained in culture and grows as poorly 
differentiated elongated cells. Ultrastructural and immunocytochemistry analysis revealed 
characteristic features of adenocarcinoma. Cytogenetic studies showed that LM2 cells are 
fundamentally hypotetraploid. They express metalloproteinases (MMP) and show high 
levels of plasminogen activator type urokinase (uPA). They were sensitive to nitric oxide 
(NO)-mediated cytotoxicity when NO derived from an exogenous donor. In vivo, although 
LM2 cells were able to grow in the lungs, they could not metastasize to the same target 
organ from s.c. primary tumors. The LM2 mouse mammary adenocarcinoma cell line is a 
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suitable model to examine different aspects of tumor biology [Hegyesi et al., 2007], in 
particular those related to the different pathways involved in the metastatic cascade and in 
the cytotoxicity mediated by NO. LM2 cells, kindly provided from the laboratory of Dr. 
Lucas Colombo (Research Area, Institute of Oncology Angel H. Roffo, C1417DTB, Buenos 
Aires, Argentina), were grown in DMEM medium supplied with 1% L-Glutamine and 
Penicillin/ Streptomycin and 10% FBS. 
3.2 Radiation induced gene expression in LM2 
It has been reported that GDF-15 is widely expressed, at low levels in different epithelial 
cells, but its expression is dramatically increased following inflammation, injury, or 
malignancy [Bauskin et al., 2006]. Our qRT-PCR data showed elevated transcriptional 
response of GDF-15 in LM2 cells, irradiated with 2 Gy and analyzed 2 hour later, but 
expression of TGF- did not show the similar expression changes in these cells. It is likely 
that LM2 cells differently express TGF-and the GDF-15. 
The 2 Gy-induced changes in the transcript level of the GDF-15 and TGF- gene were 
measured by qRT-PCR. The observed changes are shown in Figure 2. GDF-15 mRNA levels 
increased 2 hours after exposure with 2 Gy (p<0.011 with one-way ANOVA). Expression of 
TGF- mRNA decreased 2 hours after exposure with 2 Gy (p<0.039 with one-way ANOVA). 
The dose-dependency of radiation-induced expression of GDF-15 at 2 hours with -ray 
exposure with doses 0.1 Gy, 2 Gy and 4 Gy was 196.9%± 17, 201.01%± 25 and 585.63%± 81, 
respectively in LM2 cells.  
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Fig. 2. 2 Gy induced expressional changes of GDF-15 and TGF- measured by real time PCR. 
Real-time PCR was performed to test for radiation induced changes in GDF-15 and TGF-ǃ 
mRNA expression. LM2 cells showed significant increased GDF-15 and decreased TGF-ǃ 
mRNA expression after irradiation at 2h. The mRNA expression is normalized to the 
unirradiated controls. Error bars represent standard errors. Measurements were performed 
in duplicate, and experiments were repeated three times. 
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The identification of radiation-inducible genes, especially those exhibiting a dose-dependent 
response, not only expands our knowledge of the mechanisms underlying the diverse 
biological effects induced by ionizing radiation, but provides candidates for developing 
novel biomarkers of radiation injury. 
3.3 Development of GDF-15 knocked down LM2 stable cell line 
To establish a suitable cellular system to investigate a possible role of GDF-15 in breast 
cancer progression, we examined effect of GDF-15 silencing in LM2 cell lines.  
To create GDF-15 expression silenced cell lines, we used plasmid vector construct kindly 
provided by Dr. Lambert (Anschutz Medical Campus, UCD-School of Medicine, Aurora, CO, 
USA). According to the manufacturer’s protocol of OriGene shRNA (OriGene, Rockville, MD, 
USA) with different gene-specific shRNA expression pRS vectors (mouse GDF-15 shRNA) 
transfected into subconfluent LM2 cells for 48 hours. After transfection, puromycin (15 μg/ml) 
selection was commenced and maintained for two weeks to obtain the puromycin-resistant 
clones. Four clones were analyzed. The expectation was that a range of knockdown efficiencies 
will be achieved with at least 1 to 2 clones resulting in very high levels of knockdown. 
Expression of GDF-15 mRNA was measured by qRT-PCR. (We named the stable shGDF-15 
expressing LM2 cells as “shGDF-15#1; #2; #3 or #4”.) The puromycin-resistant stable 
transfected LM2 cells were propagated in the continual presence of puromycin (15 μg/ml).  
Total RNA was isolated and used as a template to quantify the level of suppression of GDF-
15 by qRT-PCR. GDF-15 expression data from several transfected clones is shown in Figure 
3. Results showed that GDF-15 expression was indeed almost completely knocked down in 
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Fig. 3. The efficiency of down regulation of the GDF-15 gene was determined by qRT-PCR. 
the transfected cells shGDF-15#1 and shGDF-15#4 at mRNA levels, whereas no effect was 
observed in scrambled shRNA–transfected control cells (LM2 #N). It can be seen that the 
expression of GDF-15 was most suppressed in the cell clone shGDF-15#1, which was 
generated from cells transfected with shRNA vector GDF-15#1. Therefore, the clone LM2-
www.intechopen.com
 
Breast Cancer – Recent Advances in Biology, Imaging and Therapeutics 
 
388 
shGDF-15#1 was used for further investigation of the involvement of GDF-15 in the cellular 
response to radiation. 
The effect of 2 Gy exposure on expression of GDF-15 was almost completely abolished in 
GDF-15 silenced LM2 when compared with LM2#N + 2 Gy IR, as see on Figure 4 (2Gy 
induced elevation of GDF-15 in LM2#N: GDF-15 201%, LM2-shGDF-15#1: GDF-15 119,31%, 
was measured , respectively p<0.05). 
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Fig. 4. 2 Gy induced expressional changes of GDF-15 measured by real time qRT-PCR. 
3.4 Effect of GDF-15 silencing on survival of LM2 cells 
In human colorectal HCT-116 cells, knockdown of GDF-15 impairs cell growth and survival 
[Baek et al, 2001]. Overexpression of GDF-15 in sense GDF-15 cells enhanced basal and 
indomethacin stimulated apoptosis, whereas the antisense GDF-15 exhibited an attenuated 
response to indomethacin treatment. Knockdown of GDF-15 in nasopharyngeal NPC cells 
resulted in growth delay and a reduction of clonogenic survival in response to radiation 
[Chang et al, 2007].  
To gain a better understanding of how GDF-15 is involved in radiation response in 
mammary carcinoma cells, we determined the effects of stable knockdown of GDF-15 on 
radioresistance through expression of shRNA targeting GDF-15. In our study clonogenic 
survival assays further demonstrated that suppression of GDF-15 increased the sensitivity of 
LM2 shGDF-15#1 cells to radiation doses of up to 2 Gy (Figure 5). Our results suggest that 
cells with reduced GDF-15 expression were sensitive to radiation-induced cell death (Figure 
5, p<0.05, LM2#N vs. LM2-shGDF-15#1). For statistical analysis Pearson’s t test were used. 
Differences were accepted as statistically significant if p<0.05. These results further validate 
the specific role of GDF-15 pathway in regulation of radioresistance, and suggest that high 
level of expression of GDF-15 may be required for radioresistance of breast cancer cells. 
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Fig. 5. Clonogenic survivals of irradiated LM2 cells after stable shGDF-15#1 transfection. 
Clonogenic survival was measured after stable transfection with GDF-15-specific shRNA 
(shGDF-15#1) in combination with irradiation at 2 Gy and 4 Gy. To examine the additional 
effects of irradiation all values of clonogenic survival at 0 Gy were set arbitrarily at 1. GDF-
15 depleted cells showed significant increased radiosensitivity, after irradiation with 2 Gy or 
4 Gy, respectively. Data represent the average values (± SE) of at least three independent 
experiments. (* p < 0.05). 
3.5 Effect of GDF-15 silencing on in vivo tumor growth 
The LM2 mammary adenocarcinoma and Balb/c mice was used for tumor growth delay 
assay. The mice were all female and 10 weeks old at the start of treatment. Exponentially 
growing cells cultured in DMeM medium supplemented with 10% fetal bovine serum were 
washed in PBS buffer and inoculated subcutaneously into the right flank. The growth delay 
assay was performed when the LM2 tumor reached 2 mm in average diameter, (6 days after 
inoculation).  
In order to investigate the relevance of GDF-15 expression in tumor development, we 
examined whether GDF-15 silencing by shGDF-15 affects tumor growth in vivo. We used 
stable transfected LM2 shGDF-15#1 cell line or empty vector control LM2#N cells. The 
proliferation rate of LM2#N, and LM2-shGDF-15#1 cells, in vitro, was not affected 
significantly by GDF-15 expression and was comparable to the proliferation rate of the 
parental control cell line (Figure 6a).  
We then analyzed whether GDF-15 silencing could affect the tumor growth capacity of these 
cells in vivo. The GDF-15 silencing clones LM2-shGDF-15#1 and the control LM2#N were 
injected subcutaneously into the flanks of the Balb/C mice. Tumor growth was observed 
and measured over a time period of 4 weeks (Figure 6b). Growth was delayed in GDF-15 
knockdown cells, while the cells of the control pool retained high proliferative properties. 
Since the proliferation rate of GDF-15 silencing cells in vitro was almost similar to the 
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proliferation rate of the control cells, inhibition of tumorigenicity by silencing of GDF-15 
observed in vivo might involve in part a paracrine effect of GDF-15 on the host cells. 
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Fig. 6. a Effect of GDF-15 expression on cell growth in vitro. 
Cells numbers were determined by manual counting using hemocytometer. Data are expressed as a 
mean± SE measured from three independent experiments but the difference on growing rate was not 
statistically significant. 
In agreement with our result, Boyle et al. reported that melanoma cell lines and metastatic 
melanomas expressed larger amounts of GDF-15 than melanocytes, nevi, and primary lesions 
of melanoma. Knockdown of GDF-15 expression in three melanoma cell strains tested resulted 
in a significant decrease in tumorigenicity but did not affect anchorage-independent growth of 
the cells. The authors demonstrated that, in melanoma cells, expression of GDF-15 was at least 
partially dependent on the mitogen-activated protein kinase (MAPK) pathway and that stem 
cell factor–mediated c-Kit activation enhanced the level of GDF-15 [Boyle et al., 2009]. The 
decrease in GDF-15 levels by shRNA constructs reduced melanoma tumorigenesis, but did not 
alter cultured cell growth, suggesting a unique function other than growth control. GDF-15 
may positively affect tumor progression via the Src-dependent transactivation of ErbB family 
receptors. Any activation of ErbB family tyrosine kinases by GDF-15 was likely to promote the 
ability of tumor cells to activate oncogenic signaling, most notably signaling of Akt and 
MAPKs in SK-BR-3 human breast cancer cells [Park et al., 2010]. 
In contrast, Baek and co- workers described an anti-tumorigenic function of GDF-15 
ectopically expressed in the colon carcinoma cell line HCT-116 [Baek et al., 2001]. Ectopic 
expression of GDF-15 in the glioblastoma cell line LN-Z308, which are insensitive to GDF-15 
mediated growth suppression in vitro, completely abolished tumorigenicity in vivo 
[Albertoni et al., 2002]. Additionally, GDF-15 expression in MCF-7 cells could directly 
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inhibit tumor growth in an orthotopic tumor model using MCF-7 cells that overexpress 
GDF-15 [Martinez et al., 2006]. 
 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0 5 10 15 20 25 30
days
tu
m
o
r 
v
o
lu
m
e
 (
m
m
3
)
LM2 #N
LM2-shGDF-15 #1
**
**
*
 
Fig. 6. b Effect of GDF-15 expression on tumor growth in vivo. 
For statistical analysis Pearson’s t test were used. Differences were accepted as statistically significant if 
*p<0.05 and **p<0,001 
We speculated that the inhibitory or tumor promoter effect of GDF-15 on different tumor 
cell growth might be due to a defect in the TGF-/Smad signaling pathway or the presence 
of the wild type p53 mediated cascade. 
3.6 Therapeutic efficiency of combined radiotherapy with stable overexpression of 
shGDF-15 in preclinical mouse mammary tumor model 
Irradiation was carried out using a cobalt-60 source at a dose rate of 0.45 Gy/min-, the total 
given dose was 4 Gy. For the growth delay assay, mice were given local irradiation. The two 
dimensions of each tumor were measured every second day with digital calipers, and the 
tumor volume was estimated using the formula Π/6 x w1x w22 product of the longest (w1) 
and shortest (w2) dimensions. 
To assess the long-term consequences of GDF-15 depletion in LM2 shGDF-15#1 cells on 
radiosensitivity, 4 Gy local exposure was applied, followed by implantation into Balb/c 
mice, to monitor the tumor growth. Cells depleted of GDF-15 showed no difference in 
tumor-forming capacity compared with LM2#N control cells (Figure 7), consistently with 
the modest in vitro effect. However, significant radiation-delayed tumor growth was 
observed compared with unirradiated LM2-shGDF-15#1 cells. The cytotoxic effect of 4  
Gy exposure was significantly enhanced in GDF-15 depleted LM2 cells (p<0.05 in one-way 
ANOVA). 
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Fig. 7. Enhanced cytotoxicity and antitumor activity of a combination of GDF-15 silencing 
and ionizing radiation. 
LM2 #N or LM2-shGDF-15#1 syngrafts grown in Balb/c mice were treated with ionizing radiation and 
tumor growth was monitored. A week after LM2 (5x105cell/50l) cell injection, animals were give 
radiation treatment (4 Gy). 
4. Conclusion 
In order to investigate the role of GDF-15 in the cellular response to ionizing radiation, a cell 
line in which GDF-15 expression was silenced by shRNA interference was generated. In 
summary, in the present study we were able to demonstrate that GDF-15 silencing combined 
with irradiation has additive effects on clonogenic survival in-vitro, and the tumor growth 
delay in vivo. Furthermore, we showed that silencing of GDF-15 with shRNA causes 
radiosensitization of LM2 cells. This suggests that GDF-15 is an attractive target to improve the 
efficacy of radiotherapy. Additional radiobiological studies are necessary to investigate the 
role of GDF-15 and its association with radiosensitivity of other tumor cell lines. 
Based on careful dissection of the complicated series of signaling changes within multiple 
pathways, it may in the future be possible to rationally combine multiple inhibitors of these 
processes to block cell survival, including inhibition of DNA damage sensing, receptor 
activation, paracrine ligand evolution, and intracellular signaling pathway, to achieve a 
better therapeutic response to radiotherapy. 
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